explore -WSS

explore

author：explore 2025-09-07 14:10:39 - browse：26891

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Regeneron agrees to White House price limits on anti

hotspot

WSS

Food makers to regulators: Ultra

Sanders adds drug shortage policies to pandemic preparedness bill

Custom gene therapy hints at new path for rare disease treatments

Sanders adds drug shortage policies to pandemic preparedness bill

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Wikipedia

explore

entertainment

Supreme Court strikes down use of affirmative action

IRA could hurt research into orphan drugs for rare diseases

After affirmative action ruling, medical educators look to 'holistic review'

How housing is health care on Long Island

Heart attack and stroke risk calculators need revising

At Orexo, a ‘turning point’ for everything but digital health

In Memoriam: Notable people who died in 2023

Acelyrin, a rare IPO success, stumbles in its first big test

How one medical school became remarkably diverse

Biden tests positive for Covid

knowledge

STAT Virtual Event: The State of Biosimilars: What to Watch

AI can’t replace a physician’s gut feeling

Food makers tried to stack nutrition panel with preferred experts

Medicare has a new plan to address drug shortages

Acelyrin, a rare IPO success, stumbles in its first big test

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

explore

hotspot

focus

leisure time